1,964 Shares in Thermo Fisher Scientific Inc. $TMO Bought by Diversify Advisory Services LLC

Posted by Brian Himes on Aug 20th, 2026

Diversify Advisory Services LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 1,964 shares of the medical research company’s stock, valued at approximately $1,099,000.

Other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Thermo Fisher Scientific by 0.9% in the fourth quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock worth $19,778,774,000 after acquiring an additional 288,296 shares during the period. J. Stern & Co. LLP grew its position in shares of Thermo Fisher Scientific by 58,006.4% during the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock valued at $18,258,082,000 after acquiring an additional 31,455,105 shares during the period. BlackRock Inc. purchased a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth approximately $15,501,867,000. State Street Corp raised its holdings in shares of Thermo Fisher Scientific by 1.4% in the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock worth $9,633,991,000 after purchasing an additional 229,630 shares during the period. Finally, Capital World Investors grew its holdings in Thermo Fisher Scientific by 7.0% during the fourth quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock valued at $6,376,229,000 after purchasing an additional 718,669 shares during the period. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have issued reports on TMO. Royal Bank Of Canada raised their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research report on Friday, July 24th. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 price objective for the company. Morgan Stanley boosted their price objective on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Wells Fargo & Company cut their target price on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Finally, HSBC lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their price target for the company from $670.00 to $540.00 in a research report on Wednesday, June 3rd. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $619.41.

Check Out Our Latest Stock Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $614.32 on Thursday. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The stock has a market cap of $227.14 billion, a P/E ratio of 33.05, a P/E/G ratio of 2.40 and a beta of 0.85. The company has a 50 day moving average of $536.26 and a 200 day moving average of $508.51.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. During the same period in the previous year, the business earned $4.28 EPS. The business’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Insider Buying and Selling

In other news, VP Lisa P. Britt sold 5,850 shares of the stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $580.00, for a total value of $3,393,000.00. Following the transaction, the vice president owned 14,784 shares of the company’s stock, valued at $8,574,720. This represents a 28.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $574.47, for a total transaction of $5,744,700.00. Following the sale, the chief executive officer owned 123,925 shares in the company, valued at approximately $71,191,194.75. This trade represents a 7.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 52,053 shares of company stock valued at $30,643,589 in the last 90 days. 0.33% of the stock is owned by company insiders.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.